Burns J W & Co. Inc. NY Has $3.22 Million Holdings in Becton, Dickinson and Company (NYSE:BDX)

Burns J W & Co. Inc. NY decreased its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 9.5% during the 1st quarter, Holdings Channel reports. The firm owned 13,026 shares of the medical instruments supplier’s stock after selling 1,369 shares during the quarter. Burns J W & Co. Inc. NY’s holdings in Becton, Dickinson and Company were worth $3,223,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Norges Bank bought a new stake in Becton, Dickinson and Company in the fourth quarter valued at $761,798,000. Vanguard Group Inc. grew its stake in Becton, Dickinson and Company by 2.0% in the third quarter. Vanguard Group Inc. now owns 25,927,519 shares of the medical instruments supplier’s stock valued at $6,703,041,000 after acquiring an additional 516,427 shares during the period. Royal Bank of Canada increased its holdings in shares of Becton, Dickinson and Company by 28.5% during the third quarter. Royal Bank of Canada now owns 2,139,493 shares of the medical instruments supplier’s stock valued at $553,121,000 after acquiring an additional 473,914 shares in the last quarter. Morgan Stanley lifted its holdings in shares of Becton, Dickinson and Company by 4.5% in the 3rd quarter. Morgan Stanley now owns 10,200,213 shares of the medical instruments supplier’s stock worth $2,637,062,000 after purchasing an additional 435,168 shares in the last quarter. Finally, Cooke & Bieler LP grew its position in Becton, Dickinson and Company by 117.1% in the 4th quarter. Cooke & Bieler LP now owns 710,932 shares of the medical instruments supplier’s stock valued at $173,347,000 after purchasing an additional 383,485 shares during the period. 86.97% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the stock. Barclays lifted their price objective on shares of Becton, Dickinson and Company from $305.00 to $312.00 and gave the company an “overweight” rating in a report on Monday, May 6th. The Goldman Sachs Group initiated coverage on Becton, Dickinson and Company in a report on Thursday, May 30th. They set a “buy” rating and a $274.00 price target for the company. Finally, StockNews.com downgraded shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a report on Thursday. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, Becton, Dickinson and Company has a consensus rating of “Moderate Buy” and an average target price of $280.17.

Insider Activity

In related news, EVP Michael David Garrison sold 1,715 shares of the business’s stock in a transaction dated Tuesday, April 30th. The stock was sold at an average price of $232.81, for a total value of $399,269.15. Following the sale, the executive vice president now directly owns 5,381 shares in the company, valued at approximately $1,252,750.61. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,715 shares of the stock in a transaction on Tuesday, April 30th. The stock was sold at an average price of $232.81, for a total transaction of $399,269.15. Following the sale, the executive vice president now owns 5,381 shares in the company, valued at $1,252,750.61. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Thomas J. Spoerel sold 300 shares of Becton, Dickinson and Company stock in a transaction on Monday, June 10th. The shares were sold at an average price of $239.31, for a total value of $71,793.00. Following the completion of the transaction, the senior vice president now owns 1,976 shares of the company’s stock, valued at $472,876.56. The disclosure for this sale can be found here. Insiders have sold 8,615 shares of company stock valued at $2,033,381 in the last 90 days. Insiders own 0.31% of the company’s stock.

Becton, Dickinson and Company Stock Performance

Shares of NYSE:BDX traded up $2.77 during midday trading on Friday, reaching $233.71. The company had a trading volume of 2,404,003 shares, compared to its average volume of 1,471,420. The stock has a market cap of $67.54 billion, a P/E ratio of 51.48, a P/E/G ratio of 2.02 and a beta of 0.44. The company’s 50 day moving average price is $234.36 and its 200 day moving average price is $237.84. The company has a current ratio of 1.41, a quick ratio of 0.97 and a debt-to-equity ratio of 0.62. Becton, Dickinson and Company has a 52-week low of $224.00 and a 52-week high of $287.32.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Thursday, May 2nd. The medical instruments supplier reported $3.17 earnings per share for the quarter, beating analysts’ consensus estimates of $2.97 by $0.20. Becton, Dickinson and Company had a net margin of 6.76% and a return on equity of 13.90%. The firm had revenue of $5.05 billion for the quarter, compared to analysts’ expectations of $5.04 billion. During the same period in the previous year, the company earned $2.86 earnings per share. The company’s quarterly revenue was up 4.6% on a year-over-year basis. As a group, sell-side analysts anticipate that Becton, Dickinson and Company will post 13.04 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, June 28th. Shareholders of record on Monday, June 10th were paid a $0.95 dividend. The ex-dividend date was Monday, June 10th. This represents a $3.80 annualized dividend and a dividend yield of 1.63%. Becton, Dickinson and Company’s payout ratio is presently 83.70%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.